Current diabetes and metabolic health news selected for patient safety, public usefulness, novelty, and evidence strength.News posts summarize source material in plain language and include practical takeaways. They are not individualized medical advice and should not replace clinician guidance.
A pediatric review found GLP-1 medicines may help selected children and teens with obesity or type 2 diabetes, but long-term safety data remain limited.
A nationwide Korean cohort study linked continuous glucose monitoring with lower rates of several serious complications in adults with type 1 diabetes. The findings are important, but observational.
An ENDO 2026 real-world study linked semaglutide with fewer bone fractures than several other weight-loss medicines in adults with type 2 diabetes. The finding is interesting, but it does not prove semaglutide prevents fractures.
FDA granted accelerated approval for Tzield in children ages 8 to 17 recently diagnosed with Stage 3 type 1 diabetes. Here is what families should know.
